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Peptide aptamers are artificial recognition molecules that
consist of a variable peptide sequence inserted into a con-
stant scaffold protein [1]. The features that distinguish
peptide aptamers from other classes of constrained com-
binatorial proteins (such as antibodies, antibody fragments
and other non-antibody scaffold-based molecules) include
their small size, their simple design and their disulfide-
independent folding; the latter enables them to function
inside living cells, unlike antibodies (Figure 1).
Peptide aptamers have been selected, using yeast two-hybrid
methods, to bind to a wide range of cellular, viral and
bacterial target proteins involved in a variety of regulatory
pathways [2]. In most cases they have a high binding
specificity, enabling them to discriminate between different
closely related proteins within a functional family, or even
between different allelic variants of a given protein [3]. In all
cases, some of the aptamers tested have been shown to inhibit
the function of their cognate targets and to cause phenotypes
in the experimental models in which they were expressed. The
use of peptide aptamers has thus enabled the dissection of
molecular regulatory pathways by specifically probing protein
functions, or sometimes even protein interactions.
The excellent recognition specificity and high binding
affinity typical of peptide aptamers have suggested that they
could be used in the many protein detection methods for
which antibodies are currently used. The work by Wälti and
colleagues published in this issue of Journal of Biology [4]
turns this possibility into reality, by establishing that
peptide aptamers can be immobilized on microarrays,
which can then be used to detect and quantify proteins
from complex solutions.
At least three important challenges must be overcome in
order to generate microarrays that enable protein analysis at
a proteomic scale. Wälti and colleagues [4] offer convincing
solutions to each of them. A first challenge is to obtain
collections of binding reagents that can specifically recog-
nize proteins (and ideally the many isoforms generated by
differential splicing and post-translational modifications)
and also whose properties, such as stability and target
binding, are homogeneous when arrayed on solid surfaces.
In contrast to antibodies, which tend to be fragile, the
simple design of peptide aptamers confers a greater robust-
ness and probably enhances long-term stability. Moreover,
peptide aptamers have relatively homogeneous target
binding affinities [5], which is useful in protein detection as
comparable protein levels generate comparable detection
signals. The authors [4] used a new aptamer scaffold (STM,
derived from stefin A, an intracellular inhibitor of cathep-
sins) instead of thioredoxin A, which has been the scaffold
used most in other peptide aptamer applications. The STM
scaffold has been engineered to abolish all its interactions
with human proteins [6]; this feature should provide a
better signal-to-noise ratio in protein detection.
A Ab bs st tr ra ac ct t
Peptide aptamers are combinatorial recognition proteins that were introduced more than ten
years ago. They have since found many applications in fundamental and therapeutic research,
including their recent use in microarrays to detect individual proteins from complex mixtures.
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out compromising the sensitivity and specificity of protein
detection. Wälti and colleagues [4] used a masking/un-
masking procedure in which closely spaced gold electrodes
were ‘functionalized’ by the attachment of specific aptamers;
the electrodes were more than an order of magnitude smaller
than the feature size currently used in protein arrays. These
arrays are produced using conventional silicon manufac-
turing technology, which means that aptamer arraying
could reach the nanometer scale in the future.
A third challenge is to develop very sensitive protein detec-
tion methods that do not compromise the structures of the
proteins to be detected and that allow high-density multi-
plex binding measurements. The authors [4] opted for a
label-free, electrochemical method that monitors local
variations in the impedance of the electrochemical layer
above the surface of the gold electrode. Capture of protein
molecules by an aptamer-functionalized electrode perturbs
the electrical properties of the layer and thus its impedance,
as measured by applying an electrochemical potential to the
electrode (Figure 2).
Using this method, Wälti and colleagues [4] show that an
array of ten peptide aptamers can detect target proteins from
complex mixtures, at a sensitivity that is relevant to that
required to study clinical samples, and with a linear dynamic
range that covers more than three orders of magnitude.
This work opens the way to an important extension of the
therapeutic research applications of peptide aptamers,
which are already used throughout the multi-step process of
drug discovery (Figure 3) [1]. The inadequate validation of
therapeutic targets is widely recognized as a major cause of
high attrition rates and productivity decrease in drug
discovery. The ability of peptide aptamers to selectively
target and modulate the function of intracellular proteins
makes them valuable tools for target validation, as they
introduce perturbations that differ from those caused by
gene knockout or knockdown methods [7] and that are
arguably much more similar to perturbations caused by a
small-molecule drug.
The mode of action of bioactive peptide aptamers has been
explored in several studies. In most cases, aptamers have
been shown to inhibit protein-protein interactions [3,7-9].
Some aptamers are selected for their ability to bind to
transcription factors and have also been shown to inhibit
protein-DNA interactions, either by masking the DNA-
binding domain [10] or by inhibiting a protein interaction
required for DNA binding [10,11]. Recently, however, an
alternative mode of inhibition has been described for
peptide aptamers selected against the hepatitis B virus core
protein and the human papillomavirus E6 oncoprotein
[12]. In both cases, fusion proteins comprising a histidine
tag, an aptamer and the herpes simplex virus VP22 protein
(which has been shown to improve gene transfer by
spreading from a primary transfected cell to surrounding
cells) were found to sequester their cognate targets into
perinuclear inclusion bodies called aggresomes, thus
depleting the pool of soluble target proteins from the cells.
This sequestration phenomenon will probably be observed
less frequently when ‘naked’ peptide aptamers are
expressed. Finally, some peptide aptamers have been shown
to activate rather than inhibit the function of their cognate
target proteins, thus confirming that aptamer-induced pertur-
bations are more similar to those caused by small molecules
than to those caused by reverse genetics methods [13,14].
Beyond the validation of target candidates, phenotypic
selection of peptide aptamers can be a powerful approach
for the identification of new therapeutic targets. Peptide
aptamers have been isolated for their ability to confer
phenotypes on yeast [15-17], bacteria [18] and human [14]
cells. Some of these isolated aptamers have been used as
baits to perform yeast two-hybrid screening of genomic or
cDNA libraries and to identify their cognate targets. These
interrogations of biological pathways have revealed new
functions for open reading frames and proteins or have
linked them to pathways in which they were previously not
known to be involved.
Peptide aptamers can also have a direct impact on the
discovery of new therapeutic molecules in two different
ways. First, it is conceivable that peptide aptamers could
themselves be used as biotherapeutics. Peptide aptamers
selected for their ability to bind to the intracellular domain
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Comparison between different constrained combinatorial recognition
proteins, showing their approximate size and complexity (not to scale).
IgG, immunoglobulin G; scFv, single-chain Fv antibody fragment.
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scFvof the epidermal growth factor receptor and to the
transcription factor Stat3 were fused to a polyarginine
protein transduction domain (PTD), produced in Escherichia
coli, and shown to inhibit the growth of tumor cells in vitro
[10,19]. More recently, peptide aptamers directed against
the prion-related protein PrpC  were produced in E. coli
without a PTD, added to prion-infected neuroblastoma
cells, and shown to reduce formation of the pathogenic
prion isoform PrpSc [20]. Lengthy preclinical studies will be
needed to determine whether peptide aptamers are likely to
become biotherapeutic molecules, but this exciting prospect
is worth the effort.
Peptide aptamers are also used to guide the discovery of
small-molecule drugs targeting specific, alternative mole-
cular surfaces on protein targets. A straightforward approach
aimed at mapping aptamer-binding sites on target proteins
has been developed [1]. When available, this structural
information brings a whole new dimension to target
validation, because what is validated is a specific molecular
surface on a target protein [1]. When this surface is deemed
‘druggable’ (accessible to drug-like small molecules), the
cognate peptide aptamer can be used like a ‘cross-hair’ in a
high-throughput screening assay to identify small molecules
that disrupt the target-aptamer interaction. This displace-
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An electrochemical protein detection method using a peptide aptamer microarray [4]. A sample containing five different proteins is shown on the
left, and an array of 12 different peptide aptamers is shown on the right (not to scale). Large gray spheres represent the aptamer scaffold protein;
small colored spheres represent the aptamer variable regions, which confer binding specificity to cognate target proteins; and large colored shapes
represent the cognate target proteins of the aptamers with matching colors. Protein detection is illustrated only for the first row of peptide
aptamers. The binding of a protein to its cognate peptide aptamer perturbs the electrochemical properties of the layer above the electrode, which
alters the impedance and its phase, as measured by applying an electrical signal of varying frequency to each electrode. An alteration in impedance is
proportional to the amount of captured protein.
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Peptide aptamer microarrayment assay rests on the premise that a peptide aptamer and
a small molecule that bind to the same molecular surface
on a target protein probably trigger the same biological
effects. A duplex high-throughput yeast two-hybrid assay
has been developed and is now being used against various
target proteins [1,21].
Analytical protein microarrays will probably have a signifi-
cant impact on many areas of fundamental and therapeutic
research [22] (Figure 3). The robustness and the homo-
geneous behavior of peptide aptamers conferred by their
simple design should greatly facilitate the development and
use of peptide-aptamer-based microarrays, which will offer
a valuable alternative to antibody and antibody-fragment
microarrays. However, two important problems will need to
be addressed to scale peptide-aptamer-based microarrays up
to a level at which they will deliver all their benefits. First,
the coupling method used by Wälti and colleagues [4] must
be improved in order to produce high-complexity arrays
rapidly. Second, high-throughput peptide aptamer selection
must be made possible. Recent improvements in the yeast
two-hybrid selection of peptide aptamers [23] combined
with the use of automated procedures [24] will help achieve
a higher selection throughput, but the use of in vitro
selection methods such as the bacterial flagellum display
system [25] will probably be required to assemble
proteome-scale collections of peptide aptamers.
Astronomers teach us that one of the most conspicuous
phenomena on the surface of the sun is the appearance and
disappearance of dark, irregularly shaped areas caused by
violent eruptions; these are known as sunspots. Although
sunspots can occur unexpectedly, a regular cycle of sunspot
activity has been observed, with both a minimum and
maximum level occurring approximately every 11 years.
Around 11 years ago, a significant eruption occurred in the
field of combinatorial biology with the first publication
describing the selection of peptide aptamers by a yeast two-
hybrid method [5]. Over the past ten years, as the techno-
logy has matured and found various applications, a number
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Fundamental and therapeutic research applications of peptide aptamers. The advances shown in the middle column can be used for the applications
shown in fundamental (left) and therapeutic (right) research. Y2H, yeast two-hybrid.
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Fundamental research Therapeutic research Peptide aptamersof subsequent eruptions have occurred. A recent series of
exciting reports exploring modes of action of peptide
aptamers [7,12,14,20] and describing new technology
developments and applications [1,4,21,23] marks an
intense period of activity. With the latest remarkable
eruption reported in this issue of Journal of Biology [4], we
are now undoubtedly witnessing the 11-year switch of
peptide aptamers.
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